DURECT Corporation (DRRX)
NASDAQ: DRRX · Real-Time Price · USD
0.950
+0.092 (10.72%)
Dec 20, 2024, 4:00 PM EST - Market closed
DURECT Revenue
DURECT had revenue of $1.93M in the quarter ending September 30, 2024, with 10.49% growth. This brings the company's revenue in the last twelve months to $8.59M, down -6.53% year-over-year. In the year 2023, DURECT had annual revenue of $8.55M, down -55.67%.
Revenue (ttm)
$8.59M
Revenue Growth
-6.53%
P/S Ratio
3.38
Revenue / Employee
$148,172
Employees
58
Market Cap
29.49M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.55M | -10.74M | -55.67% |
Dec 31, 2022 | 19.28M | 5.31M | 37.96% |
Dec 31, 2021 | 13.98M | -16.13M | -53.58% |
Dec 31, 2020 | 30.11M | 5.04M | 20.09% |
Dec 31, 2019 | 25.07M | 9.80M | 64.15% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nortech Systems | 135.57M |
Accelerate Diagnostics | 11.91M |
Beyond Air | 2.34M |
IGC Pharma | 1.18M |
CytoMed Therapeutics | 330.25K |
Incannex Healthcare | 86.00K |
DRRX News
- 26 days ago - DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million - PRNewsWire
- 5 weeks ago - DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update - PRNewsWire
- 6 weeks ago - DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - PRNewsWire
- 2 months ago - DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 - PRNewsWire
- 3 months ago - DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - PRNewsWire
- 3 months ago - DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - PRNewsWire
- 4 months ago - DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript - Seeking Alpha